SUMMARY, EXPLANATION AND LIMITATIONS:
The antibody reacts with the CD19 antigen which is also known as B4. CD19 is a Type I membrane glycoprotein with a molecular weight of 95 kDa. CD19 is involved in the development, activation and differentiation of B-cells. The molecule is expressed on the cell membrane of normal B-cells and pre-B-cells and downregulated during terminal maturation to plasma cells, which are negative for CD19. Positive immunostaining of CD19 is also observed on the cell membrane of follicular dendritic cells as well as in early stages of myelomonocytic cells. T-cells, NK-cells, monocytes and granulocytes are negative for CD19. CD19 is used as a pan-B cell marker. Compared to CD20, the classical pan-B marker in immunohistochemistry, CD19 is somewhat lower expressed in some B-cell neoplasias.
Immunogen: Synthetic peptide according to the C-terminus of human CD19.
Staining pattern: Cytoplasmic membrane.
Positive control: Tissue sample from tonsil.
This antibody is designed for the specific localization of human CD19 using IHC techniques in formalin-fixed, paraffin-embedded tissue sections.
CD19 is used as a pan-B cell marker. Compared with CD20, the classical pan-B marker in immunohistochemistry, the expression of CD19 is somewhat lower in some B cell neoplasms.